The content on this site is intended for healthcare professionals only
Dr Peter Borchmann speaks to ecancer about a comprehensive analysis of treatment-related morbidity and progression-free survival in the GHSG phase III HD21 trial.
The GHSG-HD21 trial for newly diagnosed adult patients with advanced-stage classical Hodgkin lymphoma (AS-cHL) compares the BrECADD regimen (Brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone) to eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) in a PET adapted approach.
The study found that the novel BrECADD regimen showed the highest 3-yr PFS rates reported to date in a randomised clinical trial in advanced-stage cHL. This analysis suggests that the unexpectedly high and improved efficacy of the new BrECADD regimen compared to eBEACOPP is a direct consequence of its improved tolerability and deliverability.
The results show that the optimised risk-benefit ratio of the BrECADD regimen combined with the individualised PET2-guided treatment duration sets a new benchmark for the treatment of adult patients with newly diagnosed advanced-stage cHL
Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients
30 minute infusion of isatuximab shows potential in newly diagnosed multiple myeloma
SIOG 2024: Updates in haematology
Isa-VRd shows greater efficacy compared to VRd in transplant-ineligible NDMM patients
Optimising benefit-risk and minimising impact on quality of life with BCMA-targeting agents in an outpatient setting
Understanding the remaining unmet needs in a post ASCT NDMM setting
Approaches to risk stratification in high risk myeloma
Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM
Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients
